



Dopamine Signaling Pathway in Health and Disease

Guest Editors:

Prof. Dr. Floriana Volpicelli

Department of Pharmacy, School
of Medicine and Surgery,
University of Naples Federico II,
80131, Naples, Italy

**Prof. Dr. Maria Concetta
Miniaci**

Department of Pharmacy, School
of Medicine and Surgery,
University of Naples Federico II,
80131, Naples, Italy

Dr. Luisa Speranza

Dominick P. Purpura Department
of Neuroscience, Albert Einstein
College of Medicine, 1300 Morris
Park Avenue, Bronx, NY 10461,
USA

Deadline for manuscript
submissions:
closed (31 January 2024)

Message from the Guest Editors

Dopamine is a key neurotransmitter modulating multiple and essential physiological functions of the central nervous system, including motor behavior, affective and emotional states, reward and reinforcement behaviors, and other higher cognitive functions. The four major dopaminergic pathways are the nigrostriatal, the mesocortical, the mesolimbic, and the tuberoinfundibular pathway.

Dysfunction in the dopaminergic transmission is recognized as a core alteration in several neurological and psychiatric disorders, including Parkinson's disease, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD), and addiction.

This Special Issue on the “Dopamine Signaling Pathway in Health and Disease” will present a selection of original research papers and reviews concerning the cellular and molecular mechanisms underlying dopaminergic neuromodulation under physiological conditions and in preclinical cellular and animal models of dopaminergic neurodegeneration as well as novel potential pharmacological approaches for dopamine-related disorders.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)